Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 23, 2019
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - March 23, 2019

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/14/19 - 208 Plant Construction Project for New Influenza Vaccine Production Workshop [TenderNews.com - Tenders (India)]
208 Plant Construction Project for New Influenza Vaccine Production Workshop more info: Location: China BidDate: 3/ 19/ 2019 Tender Country: China Tender Type: Tenders Tendering Authority: China National Scientific Instruments and Materials Co., Ltd. Tendering Authority Address: Address: Add.: No.1 building, No.
3/14/19 - Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practices for Positron Emission Tomography Drugs
Agency: " Food and Drug Administration, HHS." Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the no
3/14/19 - Alkahest to Present Results from Phase 2a Open Label Study of AKST4290 in wet AMD at Retina World Congress
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, will present the results from its open label study evaluating AKST4290 for the treatment of wet age-related macular degeneration in treatment-nave patients at the Retina World Congress in Fort Lauderdale, Florida
3/14/19 - Allergan to Present New Data - "Extended Duration of Intraocular Pressure (IOP) Control with Intracameral Bimatoprost Sustained-Release (SR) Implant" Highlighting Clinical Advances at the American Glaucoma Society Annual Meeting
DUBLIN, March 14, 2019/ PRNewswire/ Allergan plc,, a leading global pharmaceutical company with more than 70 years of heritage in eye care, will present new data including a late-breaking abstract for Bimatoprost SR at the Annual Meeting of the American Glaucoma Society to be held in San Francisco, California. Logistic Regression Analysis of Base
3/14/19 - Alport Syndrome Treatment Market Segmentation by Based on Distribution Channel- Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies: Fact.MR has announced the addition of the Alport Syndrome Treatment Market Forecast, Trend Anal
Rockville, MD 03/14/2019 Alport Syndrome is the hereditary genetic disorder characterized by glomerulonephritis, abnormal vision, acute hearing loss and end-stage renal disease. Alport Syndrome is also called the hereditary nephritis. According to the National Institute of Health, alport syndrome occurs in approximately 1 in 50,000 newborns.
3/14/19 - Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease
In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc., a late clinical-stage biopharmaceutical company with research ongoing in two kidney diseases, Lupus Nephritis and Focal Segmental Glomerulosclerosis, today announced a host of activities, including an initiative with The National Kidney Foundation, designed
3/14/19 - Avillion Appoints Dr David Chiswell OBE as Board Member
Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates from proof-of-concept through to regulatory approval, today announces the appointment of Dr David Chiswell OBE as a Non-Executive Director of Bond 2 Development 2 GP, the General Partner of Bond Avillion 2, the Avillion entity that en
3/14/19 - BD Announces FDA Premarket Approval For Venovo Venous Stent
WASHINGTON- Becton, Dickinson and Company announced the U.S. FDA has granted premarket approval for the Venovo venous stent, the first stent indicated to treat iliofemoral venous occlusive disease, which is obstructed or narrowed blood flow specific to the iliac and femoral veins located near the groin. We designed the Venovo venous stent in collab
3/14/19 - BD Receives U.S. FDA Approval for First Venous Stent to Treat Iliofemoral Venous Occlusive Disease
BD, a leading global medical technology company, today announced the U.S. Food and Drug Administration has granted premarket approval for the Venovo? venous stent, the first stent indicated to treat iliofemoral venous occlusive disease, which is obstructed or narrowed blood flow specific to the iliac and femoral veins located near the groin.
3/14/19 - Bempedoic Acid Study 1 Results Published in The New England Journal of Medicine Demonstrates Significant LDL-Cholesterol Lowering and Reduced Marker of Underlying Cardiovascular Inflammation, with a Similar Tolerability to Placebo
Bempedoic acid is an oral, once-daily ATP Citrate Lyase Inhibitor that reduces cholesterol and fatty acid synthesis in the liver Study 1 is the largest of a comprehensive five Phase 3 study programme investigating the benefits of bempedoic acid in patients requiring additional low-density lipoprotein cholesterol lowering Over 52- weeks, bempedoic a
3/14/19 - Biocon biosimilar plant criticized again by the FDA [Sport360]
The plant in India where Biocon makes the biosimilars it shares with Mylan was given a clean bill of health by the FDA last yearbut not for long. The most recent citation of the Bangalore plant includes only two observations, unlike in 2017 when a long list of problems led the FDA to delay approvals of the biosimilars that Mylan and Biocon were dev
3/14/19 - Biohaven Enrolls First Patient In Phase 3 Spinocerebellar Ataxia Clinical Trial Of Troriluzole
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, today announced that it has enrolled the first patient in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in...
3/14/19 - BrainStorm Announces First Patient Enrolled in Phase 2 Clinical Trial of Progressive MS
BrainStorm Cell Therapeutics Inc., a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the first patient has been enrolled in its Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous MSC-NTF cells in participants with...
3/14/19 - Bruker Announces Acquisition of Scientific Software Provider Arxspan
Bruker Corporation today announced that it has acquired Arxspan LLC, a provider of cloud-based scientific software and workflow solutions, based in Southborough, Massachusetts. Commenting on the acquisition, Dr. Falko Busse, Group President for Bruker Biospin, stated: "The Arxspan acquisition, coupled with our strategic partnership with Mestrelab
3/14/19 - CATABASIS PHARMACEUTICALS INC - 10-K - Management's Discussion and Analysis of Financial Condition and Results of Operations
The United States Food and Drug Administration, or FDA, has granted orphan drug, fast track and rare pediatric disease designations to edasalonexent for the treatment of DMD. The European Commission, or EC, has granted orphan medicinal product designation to edasalonexent for the treatment of DMD. We initiated a global Phase 3 trial of edasalonexen
3/14/19 - Celgene Seeks Approval in European Union for Ozanimod to Treat Adult RRMS [Tehran Times (Iran)]
An application has been submitted for the use of ozanimod to treat adult patients with relapsing-remitting multiple sclerosis within the European Union, according to Celgene, the developer of ozanimod. The marketing authorization application was submitted to the European Medicines Agency. By the end of March, Celgene intends to also apply for appro
3/14/19 - Clinical Resource Network (CRN), A Division Of Solomon Page, Expands Footprint Internationally
Solomon Page, a specialty niche provider of staffing solutions and executive search, announces the international expansion of Clinical Resource Network. Launched as a division of Solomon Page in 2002, CRN supports customized staffing solutions for a range of clients from Biotechs and CROs to pharmaceutical and medical device companies across N
3/14/19 - Contract Pharmaceutical Fermentation Services Market Report through 2018-2026 [ClickPress (UK)]
FactMR has actively published a new research study titled Contract Pharmaceutical Fermentation Services Market Report through 2018-2026 to its broad online database. This assessment works to discourse the major trends, opportunities and drivers motivating the contract pharmaceutical fermentation services market during 2018-2026. The insights.
3/14/19 - Contrast Media Injectors Market Expected to Behold a CAGR of 5.0% Through 2014 - 2020
Albany, NY 03/14/2019 Contrast media are used to enhance quality of medical imaging such as CT, MRI, PET/CT and ultrasound. Their value has long been recognized by radiologists and is well illustrated by their frequent use in radiology departments worldwide. Contrast media injectors are devices employed for injecting contrast media into the b
3/14/19 - Correvio Announces at the Market Offering
-Correvio Pharma Corp.,, a specialty pharmaceutical company focused on commercializing hospital drugs, today announced that it has entered into an At the Market Sales Issuance Agreement dated March 13, 2019 with Cantor Fitzgerald& Co. as agent, pursuant to which the Company may, from time to time sell, through "at-the-market" offerings on the Nasda
3/14/19 - CRISPR Market by Product, Service, End User, Worth $550.0 Mn by 2030: Top Key Players - CRISPR THERAPEUTICS, Mirus Bio LLC, Takara Bio USA, Editas Medicine: The CRISPR technology is focused on development or growth of the gene therapeutics for the tr
New York, NY 03/14/2019 CRISPR Market and Patent Landscape Report by Applications, by Products, by Technology, by Patent Activities Global Forecast, 2030.. Market Industry Reports has published a new report titled "CRISPR Technology Market- Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 2030." According to the
3/14/19 - CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol (R) Cyclo (TM) in Alzheimer's Disease
ALACHUA, FL/ ACCESSWIRE/ March 14, 2019/ CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today that the company has initiated planning for a Phase I clinical trial for treatment of Alzheimer's Disease. The Alzheimer's Association rep
3/14/19 - Cue Biopharma to Present Corporate Overview and Update at the Oppenheimer 29th Annual Healthcare Conference
Cue Biopharma, Inc., an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today that it will present a corporate overview at the Oppenheimer 29 th Annual Healthcare Conference on Tuesd
3/14/19 - Dietary Supplements Market Undertake Strapping Growth By 2019 With Archer Daniels Midland Company, Stepan Lipid Nutrition, NBTY, XanGo, Amway, Abbott, Arkopharma, The Carlyle Group, NBTY Europe &Other
Global Dietary Supplements Market is expected to reach value of USD 280.10 billion by 2025, growing at a CAGR of 9.6% during the forecast period of 2018 to 2025.. Global Dietary Supplements market is going to be great in the forecast year in terms of CAGR levels, production, Consumption, revenue, Gross margin, Cost, Gross, market share. Amway, Abot
3/14/19 - Disposable Syringe with Detachable Needle-2ml.Latex Free,Compliant to Iso 7886. 4 Flow Wrap Package.Eto Sterilized Conforming to Iso 10993-7/Iso13485:2012 Ce Certification.
Ministry/Department Office of the Chief Medical Director 14, Strand Road, 12th Floor, New Koilaghat Building Kolkata Attn: Medical/Eastern Rly. Description: Tenders are invited for Disposable Syringe with Detachable Needle-2ml.Latex Free, Compliant to Iso 7886. 4 Flow Wrap Package.Eto Sterilized Conforming to Iso 10993-7/ Iso13485: 2012 Ce...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2019 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415